Octagon Capital Advisors LP Makes New $3.26 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Octagon Capital Advisors LP bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 900,000 shares of the company's stock, valued at approximately $3,258,000. Atyr PHARMA makes up about 0.5% of Octagon Capital Advisors LP's investment portfolio, making the stock its 28th biggest position. Octagon Capital Advisors LP owned 1.07% of Atyr PHARMA as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after acquiring an additional 10,754 shares during the period. Kingswood Wealth Advisors LLC bought a new position in Atyr PHARMA in the fourth quarter valued at about $170,000. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA in the fourth quarter worth about $36,000. D.A. Davidson & CO. bought a new position in shares of Atyr PHARMA in the fourth quarter worth about $141,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Atyr PHARMA during the 4th quarter valued at approximately $144,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ATYR. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price objective for the company. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Stock Down 1.2%

Shares of NASDAQ ATYR opened at $3.24 on Tuesday. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The company's 50 day moving average price is $3.27 and its 200-day moving average price is $3.40. The company has a market capitalization of $288.37 million, a P/E ratio of -3.45 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. Equities analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Want to see what other hedge funds are holding ATYR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atyr PHARMA INC (NASDAQ:ATYR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.